Inversion Therapeutics, Inc. — Form D
Inversion Therapeutics, Inc. of BURLINGAME, CA, a company, filed a Form D exempt-offering notice with the SEC on 2025-08-27. The offering totals $11.1M, of which $6.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-08-27
- Form: D
- Accession: 0001231919-25-000167
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $11.1M
- Amount sold: $6.9M
- Remaining: $4.2M
- Investors: 4
- Date of first sale: 2025-06-20
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-555986
Issuer
- Name: Inversion Therapeutics, Inc.
- CIK: 0002077706
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2024
- Address: 1341 COLUMBUS AVENUE, BURLINGAME, CA, 94010
- Phone: 650-430-5176
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Jeremy A Caldwell, Ph.D. | Director | Burlingame, CA |
| William Michael Kavanaugh, M.D. | Director | Burlingame, CA |
| Samad Michael Wahid, M.D. | Director | Burlingame, CA |
| James A Wells, Ph.D. | Director | Burlingame, CA |
| James A Wells, Ph.D. | Executive Officer | Burlingame, CA |
More